IBRX · XBRL financial data

ImmunityBio financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (IBRX's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	0	0*	0	1	6	8*	17	26	32	38*	44	51
Revenue from contracts with customers	0	0*	0	1	6	8*	17	26	32	38*	44	51
Cost of goods and services sold	0	0*	0	0	0	0*	0	0	0	year only	0	0
Research and development	48	52*	53	51	50	35*	—	—	—	—	—	—
Selling, general and administrative	32	33*	42	49	36	42*	—	—	—	—	—	—
Total operating expenses	80	86*	95	100	86	77*	—	—	—	—	—	—
Operating income (loss)	(80)	(85)*	(95)	(99)	(80)	(69)*	(64)	(71)	(56)	(65)*	(70)	(62)
Interest expense	35	32*	29	30	29	26*	15	15	15	15*	—	—
Other income (expense)	(1)	(0)*	(0)	(0)	0	0*	(0)	(0)	(0)	(2)*	(6)	0
Income tax expense (benefit)	0	(0)*	0	0	0	0*	(0)	0	(0)	(0)*	0	0
Net income (loss)	(96)	(233)*	(134)	(135)	(86)	(59)*	(130)	(93)	(67)	(62)*	(633)	(230)
Earnings per share, basic USD per share	(0.19)	—	(0.20)	(0.20)	(0.12)	(0.08)*	(0.15)	(0.10)	(0.07)	(0.06)*	(0.62)	(0.22)
Earnings per share, diluted USD per share	(0.19)	—	(0.20)	(0.20)	(0.14)	(0.08)*	(0.15)	(0.10)	(0.07)	(0.06)*	(0.62)	(0.22)
Weighted average shares, basic millions of shares	498	—	673	687	696	733*	853	888	947	990*	1,027	1,050
Weighted average shares, diluted millions of shares	498	—	673	687	698	744*	853	888	947	990*	1,027	1,050

Fiscal quarters (IBRX's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	178	265	133	130	112	143	61	138	60	88	205	76
Marketable securities	12	1	37	88	18	6	1	16	198	154	176	282
Marketable securities, non-current	1	1	0	0	0	0	—	—	—	—	—	—
Accounts receivable	—	0	—	1	4	2	17	22	32	43	43	53
Inventory	—	0	—	2	2	8	8	7	7	1	1	2
Prepaid and other current assets	23	26	23	21	26	24	22	26	33	29	28	—
Total current assets	215	294	196	243	163	185	109	208	329	315	453	439
Property and equipment, net	152	146	144	142	139	137	135	133	130	114	113	114
Right-of-use asset	36	37	35	34	35	33	32	35	33	33	33	31
Goodwill	—	—	—	—	1	1	1	1	1	1	1	—
Total assets	432	504	401	444	365	383	304	402	519	502	647	629
Accrued liabilities	65	43	33	35	44	41	28	36	44	47	48	—
Total current liabilities	90	58	54	62	61	55	49	51	57	62	68	77
Lease liability, non-current	39	40	38	36	37	35	33	36	34	33	33	31
Total liabilities	843	1,090	1,092	1,142	1,109	871	894	972	1,042	1,001	1,516	1,674
Accumulated deficit	(2,728)	(2,962)	(3,096)	(3,230)	(3,316)	(3,375)	(3,505)	(3,597)	(3,665)	(3,727)	(4,359)	(4,590)
Total stockholders' equity	(412)	(587)	(692)	(698)	(745)	(489)	(591)	(571)	(524)	(500)	(870)	(1,047)
Total liabilities and equity	432	504	401	444	365	383	304	402	519	502	647	629
Common shares outstanding (cover page) millions of shares	668	674	692	697	697	853	883	945	985	1,028	1,047	1,060

Fiscal quarters (IBRX's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(96)	(233)*	(134)	(135)	(86)	(59)*	(130)	(93)	(67)	(62)*	(633)	(230)
Stock-based compensation	14*	13*	8	10*	7*	9*	10	10*	9*	9*	8	9*
Depreciation and amortization	5*	5*	5	4*	4*	4*	4	4*	4*	4*	4	4*
Net cash from operating activities	(87)*	(115)*	(107)	(100)*	(99)*	(85)*	(86)	(80)*	(69)*	(70)*	(75)	(66)*
Purchases of property and equipment	6*	8*	1	1*	3*	2*	1	1*	1*	1*	2	4*
Net cash from investing activities	(16)*	2*	(36)	(51)*	65*	10*	4	(16)*	(181)*	44*	(32)	(107)*
Net cash from financing activities	238*	201*	10	149*	16*	107*	(1)	173*	174*	55*	224	44*
Net change in cash	134*	87*	(132)	(3)*	(18)*	32*	(83)	77*	(77)*	28*	117	(130)*

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
ImmunityBio	76	51	(66)*	1.1B	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Anavex Life Sciences	118	not reported	(9.1)*	92.7M	13.0 quarters	Q3 FY26 10-QJun 30, 2026
Immunome	218	0	(62)*	113.6M	8.4 quarters	Q2 FY26 10-QJun 30, 2026
Anaptysbio	134	27*	(27)*	29.9M	6.2 quarters	Q4 FY26 10-KTJun 30, 2026
Amphastar Pharmaceuticals	224	184	51*	42.5M	—	Q2 FY26 10-QJun 30, 2026
Pacira BioSciences	206	192	57*	39.9M	—	Q2 FY26 10-QJun 30, 2026
Phibro Animal Health	61	397*	24*	not reported	—	Q4 FY26 10-KJun 30, 2026
uniQure	98	5.2	(48)*	70.1M	2.6 quarters	Q3 FY26 10-QSep 30, 2026
Cogent Biosciences	181	not reported	(77)*	173.5M	10.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.